Enterocolitis, Pseudomembranous clinical trials
The registry lists 43 studies for Enterocolitis, Pseudomembranous across more than 10 countries. 5 are recruiting or about to start. 30 of them are mainly about Enterocolitis, Pseudomembranous (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-09.
Get an email when these change. Save the Enterocolitis, Pseudomembranous studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Michael E. DeBakey VA Medical Center (5) · Genzyme, a Sanofi Company (5) · University of Wisconsin, Madison (2) · Rebiotix Inc. (2) · William Beaumont Hospitals (2) · Rockefeller University (1) · Sanofi Pasteur, a Sanofi Company (1) · Osel, Inc. (1)
What is being tested here
Drugs under test in Enterocolitis, Pseudomembranous studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 2
- Dec 2026Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT) · University of Virginia
- May 2027Stool Transplants to Treat Refractory Clostridium Difficile Colitis · Duke University
Who these studies take
Of the 4 Enterocolitis, Pseudomembranous studies recruiting now, 3 (75%) set no upper age limit and 0 (0%) stop at 75 or younger. 1 (25%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (25%) | 1 (25%) |
| 18 | 4 (100%) | 4 (100%) |
| 30 | 4 (100%) | 4 (100%) |
| 40 | 4 (100%) | 4 (100%) |
| 50 | 4 (100%) | 4 (100%) |
| 65 | 4 (100%) | 4 (100%) |
| 75 | 4 (100%) | 4 (100%) |
| 85 | 4 (100%) | 4 (100%) |
Across all 43 studies, recruiting or not: 14% stop at 75 or younger and 7% at 65; 16% take children; 0% are for women only and 0% for men only; 9% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 43 of 43. search them.
- Vancomycin Taper to Prevent Recurrent Clostridioides DifficileRecruitingNCT07328971Phase 31 country
- Emerging Indications for Hyperbaric Oxygen TreatmentNot yet recruitingNCT07240649Phase 4
- Stool Transplants to Treat Refractory Clostridium Difficile ColitisRecruitingNCT02127398Phase 21 country
- Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)RecruitingNCT04305769Phase 21 country
- Safety and Efficacy of Fecal Microbiota TransplantationRecruitingNCT04014413Not applicable1 country
- REMBRANDT: REcovery of the MicroBiome fRom Antibiotics for Dental implanTsActive, not recruitingNCT056227211 country
- Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery.TerminatedNCT03756454Phase 41 country
- A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile InfectionCompletedNCT05831189Phase 31 country
- Effect of Antibiotics on Enteric Neurons and GliaCompletedNCT05834036Phase 41 country
- Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile InfectionCompletedNCT03462459Phase 21 country
- FQ Restriction for the Prevention of CDICompletedNCT038486891 country
- Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS)CompletedNCT03931941Phase 32 countries
- Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)CompletedNCT03244644Phase 32 countries
- Multicentre Blinded Comparison of Lyophilized Sterile Fecal Filtrate to Lyophilized Fecal Microbiota Transplant in Recurrent Clostridioides Difficile InfectionCompletedNCT03806803Phase 21 country
- Bezlotoxumab Versus FMT for Multiple Recurrent CDIWithdrawnNCT05077085Phase 41 country
- Antimicrobial Stewardship Program for Clostridium Difficile Infection.CompletedNCT029514811 country
- Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile InfectionsCompletedNCT01232595Phase 22 countries
- Transplantation of Cultured Gut Microflora to Repeat Antibiotic-induced Diarrhea Due to Clostridium DifficileCompletedNCT02857582Phase 21 country
- Efficacy of Metronidazole Versus Metronidazole and Rifampin in CDAD TreatmentCompletedNCT00182429Phase 31 country
- Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in AdultsCompletedNCT01230957Phase 21 country
- Fecal Microbiota Transplantation for Severe Clostridium Difficile InfectionCompletedNCT03427229Phase 2
- Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients.CompletedNCT01477320Not applicable1 country
- Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile InfectionCompletedNCT00304356Phase 31 country
- EGESTA - Emergent GI Therapy for Severe, Complicated CDI Using Fecal Microbiota TransplantWithdrawnNCT02968511Not applicable1 country
- Phase I Trial of a Single Dose of CRS3123CompletedNCT01551004Phase 11 country
- Addition of Lactobacillus to Metronidazole in Treatment of CDADWithdrawnNCT00304863Phase 41 country
- Small Bowel Transit Time in Clostridium Difficile ColitisTerminatedNCT013097501 country
- Extended Treatment With Vancomycin for Clostridium Difficile ColitisWithdrawnNCT00861887Not applicable1 country
- Stool Transplant in Pediatric Patients With Recurring C. Difficile InfectionCompletedNCT01972334Phase 21 country
- Vancomycin vs. Nitazoxanide to Treat Recurrent C. Difficile ColitisCompletedNCT003048891 country
- Optimal Surgical Treatment Of Fulminant Clostridium Difficile ColitisTerminatedNCT01441271Not applicable1 country
- A Study of the Absorption of GT267-004 in Patients With Clostridium Difficile-Associated DiarrheaCompletedNCT00382304Phase 21 country
- A Study to Assess the Safety, Tolerability, Effectiveness and Absorption of Exodif™ Tablets in Clostridium Difficile-associated DiarrheaTerminatedNCT00466635Phase 31 country
- A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated DiarrheaCompletedNCT00106509Phase 33 countries
- A Study of GT160-246 Versus Vancomycin in Patients With Clostridium Difficile-Associated DiarrheaCompletedNCT00034294Phase 24 countries
- A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated DiarrheaCompletedNCT00196794Phase 314 countries
- Safety and Clinical Effectiveness of Oral Probiotic MIYA-BM to Prevent Recurrent Clostridium Difficile InfectionsWithdrawnNCT01077245Phase 2
- Response of Clostridium Difficile Infection to Metronidazole TherapyCompletedNCT003043691 country
- Clostridial Infection and Oral Lavage -Improving Treatment Before Illness Becomes SevereStatus unknownNCT01630096Phase 41 country
- Association Between Response to Treatment of C. Diff Colitis and Anti-C.Diff Toxin AntibodyCompletedNCT003044081 country
- Fecal Bacterial Flora in Clostridium Difficile-Associated DiarrheaCompletedNCT003048761 country
- Effect of Probiotic Lactobacilli (Lacidofil Cap®) for the Prevention of Antibiotic-Associated DiarrheaCompletedNCT010583561 country
- The Role of Synbiotics in Reducing Post-Operative Infections in Patients Undergoing Cardiac Surgery: A Pilot StudyTerminatedNCT00164099Phase 41 country